Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Rare Pediatric Disease Priority Review Voucher
Biotech
Acadia makes $100M profit from $150M pediatric voucher sale
Acadia has bagged $150 million from the sale of a priority review voucher—although the biotech will only be able to keep two-thirds of the windfall.
James Waldron
Nov 6, 2024 9:36am
AAV gene therapy biotech unveils with 10 pipeline products
Sep 12, 2024 7:00am
BridgeBio adds another $110M to coffers with voucher sale
May 13, 2022 9:45am
Jazz grabs Spark’s priority review voucher for $110M
Apr 30, 2018 10:50am
PPD establishes new center for rare disease and pediatrics
Feb 28, 2017 4:21pm
Sarepta sells Exondys 51 PRV to Gilead for $125M
Feb 21, 2017 7:24am
